Sunshine Biopharma Inc. (SBFM) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Sunshine Biopharma Inc. is a pharmaceutical company operating two primary segments: Generic Pharmaceuticals (via subsidiary Nora Pharma Inc., representing ~97% of revenue) and Over-the-Counter (OTC) Products. The company is developing proprietary drugs for oncology and antiviral treatments. The financial statements reflect retroactive adjustments for a 1-for-100 reverse stock split (April 2024) and a 1-for-20 reverse stock split (August 2024).
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value |
|---|---|
| Revenue (Sales) | $16,844,113 |
| Gross Profit | $4,710,594 |
| Gross Margin | 28.0% |
| Net Loss | $(1,778,101) |
| Operating Loss | $(2,668,046) |
| Cash and Cash Equivalents | $11,507,745 |
| Total Assets | $29,300,978 |
| Total Liabilities | $5,811,114 |
| Shareholders' Equity | $23,489,865 |
| Net Cash Used in Operating Activities | $(7,762,942) |
| Net Cash Provided by Financing Activities | $5,369,566 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 61% to $16.8 million (vs. $10.5 million in 2023), driven by expanded marketing and sales efforts by Nora Pharma.
- Margin Compression: Gross margin decreased from 36% in the prior year to 28% in 2024 due to increased manufacturing costs for generic drugs.
- Expense Increases: General & Administrative (G&A) expenses rose 11% to $7.4 million, primarily due to higher office costs ($735k increase), legal fees, and marketing spend. Consulting fees decreased significantly ($423k reduction).
- Improved Net Loss: Net loss narrowed to $1.78 million (vs. $2.60 million in 2023), aided by a reduction in operating loss and interest income.
- Capital Structure: The company completed a public offering in February 2024 raising net proceeds of $8.5 million. All Pre-Funded Warrants and Series A Warrants from this offering were exercised by June 30, 2024.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash ($11.5 million) is sufficient to fund operations and R&D for the next 24 months. However, additional capital will likely be required for future clinical trials and expansion.
- R&D Status:
- Adva-27a (Pancreatic Cancer): IND-enabling studies were paused in November 2023 following unfavorable in vitro results. The company is reviewing results for potential chemical modification.
- K1.1 mRNA (Liver Cancer): Currently in animal testing; initial xenograft studies showed tumor reduction in mice.
- SBFM-PL4 (Coronavirus): In animal testing; focused on PLpro inhibition.
- Product Pipeline: Nora Pharma plans to launch 32 additional generic drugs in 2024 and 2025, including NIOPEG (a biosimilar of NEULASTA), approved by Health Canada in April 2024.
- Risks: Revenue is heavily dependent on Canadian government drug reimbursement policies. The company has a significant valuation allowance against deferred tax assets due to historical losses.
Investor Verification Checklist
- Reverse Stock Splits: Verify share counts and warrant exercise prices have been correctly adjusted for the 1-for-100 (April 2024) and 1-for-20 (August 2024) splits.
- Warrant Liability: Confirm the status of the 13.6 million Series B Warrants outstanding (post-split) and their impact on potential dilution.
- Adva-27a Viability: Assess the likelihood of resuming development for the paused Adva-27a program and associated costs.
- Cash Burn Rate: Monitor the $7.8 million operating cash outflow against the $11.5 million cash balance to validate the 24-month runway estimate.
- Earn-Out Obligations: Review the remaining earn-out liability (~$355k USD) related to the Nora Pharma acquisition and its payment triggers.